- Three new Takeda diabetes drugs become available
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Study: Type 2 diabetes market competition heats up amid disease rate increase
- FDA clears Novo Nordisk insulin pen for children
- Novo Nordisk donates $80,000 for diabetes education in Minn.
SAN DIEGO — Amylin Pharmaceuticals and Takeda Pharmaceutical have suspended a mid-stage trial of an obesity drug over safety concerns, the two said Wednesday.
The drug makers stopped the phase-2 trial of a combination of pramlintide and metreleptin due to problems that arose in two patients related to metreleptin. Amylin said the decision to suspend the trial did not affect its investigations of metreleptin as a treatment of diabetes and hypertriglyceridemia in patients with lipodystrophy.
“The safety of patients in our clinical programs is of paramount concern to the companies,” Amylin SVP and chief medical officer Orville Kolterman said. “We have taken this precaution so that we can thoroughly investigate this finding.”